Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer
- 13 May 2019
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 176 (3) , 669-677
Abstract
Introduction The use of statins has been associated with improved survival in patients with breast cancer in several studies but results have been mixed. This study evaluates the impact of duration of statin use on breast cancer patient outcomes. Methods This is a single-institution, retrospective cohort, examining the impact of statin use on the outcomes of 1523 women diagnosed with operable breast cancer between1995 and 2015. Clinical variables were compared using Student’s t test, Fisher’s exact and Chi square tests. Overall (OS) and disease-free (DFS) survival were performed using Kaplan–Meier and Cox-Proportional Hazard (Cox-PH) analysis in the statistical software R. Results Patients were grouped by duration of statin use: never-statin user [N] (n = 1092), short (< 3 years) [S] (n = 115), moderate [M] (3–5 years) (n = 109) and long [L] (> 5 years) (n = 207) term. Over a median follow-up of 70.2 months, 138 women died (84 died of breast cancer) and 125 had disease recurrence. On multivariable Cox-PH analysis adjusting for clinical variables including metabolic comorbidities using the Charlson comorbidity index, OS in the [S] and [M] subgroups did not differ [N], while OS was improved in [L] (adjusted hazard ratio (AHR) 0.38, confidence interval (CI) 0.17–0.85, p < 0.018). DFS was also significantly improved in the [L] subgroup (adjusted HR 0.15, CI 0.05–0.48, p < 0.001). Subanalysis stratified by receptor status showed a trend towards improved DFS in all tumor subtypes including triple-negative breast cancer. Conclusions Our retrospective analyses suggest that long-term statin use (> 5 years) was associated with improved OS and DFS in women with breast cancer regardless of receptor subtype, even after adjusting for metabolic comorbidities.Keywords
Funding Information
- NIH National Cancer Institute (F32)
This publication has 25 references indexed in Scilit:
- Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient CohortPLOS ONE, 2013
- Statin Use and Reduced Cancer-Related MortalityNew England Journal of Medicine, 2012
- Prognostic Impact of Comorbidity among Long-Term Breast Cancer Survivors: Results from the LACE StudyCancer Epidemiology, Biomarkers & Prevention, 2012
- Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort StudyJNCI: Journal of the National Cancer Institute, 2011
- Simvastatin induces derepression of PTEN expression via NFκB to inhibit breast cancer cell growthCellular Signalling, 2010
- Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancerBreast Cancer Research and Treatment, 2009
- Breast Cancer Growth Prevention by StatinsCancer Research, 2006
- Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin TherapyJACC, 2005
- Statins Can Inhibit Proliferation of Human Breast Cancer Cells in VitroExperimental and Clinical Endocrinology & Diabetes, 2003
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987